20 participants
A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-07
- Start Date:
- 2023-01-23
- Completion:
- 2028-07-31
Conditions
- Autosomal Recessive Polycystic Kidney (ARPKD)
Interventions
- DRUG
No Results Yet